X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (145) 145
Publication (10) 10
Conference Proceeding (9) 9
Book Review (7) 7
Book Chapter (2) 2
Book / eBook (1) 1
Patent (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (101) 101
index medicus (98) 98
oncology (90) 90
female (75) 75
male (73) 73
middle aged (68) 68
adult (67) 67
aged (64) 64
neoplasms - drug therapy (45) 45
cancer (31) 31
camptothecin - analogs & derivatives (29) 29
pharmacokinetics (26) 26
antineoplastic agents - pharmacokinetics (25) 25
camptothecin - pharmacokinetics (24) 24
dose-response relationship, drug (24) 24
maximum tolerated dose (24) 24
antineoplastic agents - administration & dosage (22) 22
antineoplastic agents - adverse effects (20) 20
pharmacology & pharmacy (20) 20
phase-i (20) 20
drug administration schedule (19) 19
administration, oral (17) 17
area under curve (17) 17
infusions, intravenous (17) 17
antineoplastic agents, phytogenic - pharmacokinetics (16) 16
camptothecin - administration & dosage (16) 16
antineoplastic agents - therapeutic use (14) 14
phase i (14) 14
solid tumors (14) 14
treatment outcome (14) 14
irinotecan (13) 13
neoplasms - metabolism (13) 13
research (13) 13
medicine & public health (12) 12
adolescent (11) 11
cell lung-cancer (11) 11
cisplatin - administration & dosage (11) 11
protein kinase inhibitors - adverse effects (11) 11
analysis (10) 10
antineoplastic agents, phytogenic - administration & dosage (10) 10
chemotherapy (10) 10
neoplasms - pathology (10) 10
patients (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
camptothecin - adverse effects (9) 9
care and treatment (9) 9
colorectal neoplasms - drug therapy (9) 9
methotrexate (9) 9
methotrexate - therapeutic use (9) 9
pharmacology (9) 9
protein kinase inhibitors - pharmacokinetics (9) 9
rheumatology (9) 9
sn-38 (9) 9
trial (9) 9
tumors (9) 9
antirheumatic agents - therapeutic use (8) 8
biomarkers (8) 8
chromatography, high pressure liquid (8) 8
cpt-11 (8) 8
metastatic colorectal-cancer (8) 8
pharmacogenetics (8) 8
pharmacology/toxicology (8) 8
protein kinase inhibitors - administration & dosage (8) 8
resistance (8) 8
time factors (8) 8
topoisomerase i inhibitors (8) 8
topotecan (8) 8
toxicity (8) 8
animals (7) 7
antineoplastic agents, phytogenic - adverse effects (7) 7
camptothecin - blood (7) 7
cisplatin - pharmacokinetics (7) 7
cohort studies (7) 7
dosage and administration (7) 7
every 3 weeks (7) 7
metabolic clearance rate (7) 7
neutropenia - chemically induced (7) 7
safety (7) 7
young adult (7) 7
antineoplastic agents - blood (6) 6
antineoplastic agents - pharmacology (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - pharmacokinetics (6) 6
antitumor-activity (6) 6
camptothecin - therapeutic use (6) 6
child (6) 6
clinical pharmacokinetics (6) 6
combination (6) 6
drug therapy (6) 6
efficacy (6) 6
hematology, oncology and palliative medicine (6) 6
pharmacodynamics (6) 6
plasma (6) 6
polymorphisms (6) 6
thrombocytopenia - chemically induced (6) 6
active metabolite (5) 5
antineoplastic agents (5) 5
antineoplastic agents, phytogenic - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
arthritis, juvenile - drug therapy (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 12/2018, Volume 13, Issue 12, pp. e0208534 - e0208534
Journal Article
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2018, Volume 36, Issue 5, pp. 828 - 835
Purpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-767 in patients with... 
BRCA | Solid tumor | Medicine & Public Health | PARP inhibitor | Oncology | Pharmacology/Toxicology | Homologous recombination deficiency | Ovarian cancer | POLY(ADP-RIBOSE) POLYMERASE | ONCOLOGY | PHARMACOLOGY & PHARMACY | EPITHELIAL OVARIAN | Nausea - chemically induced | Benzamides - pharmacokinetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Benzamides - therapeutic use | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Food-Drug Interactions | Poly(ADP-ribose) Polymerase Inhibitors - pharmacokinetics | Anemia - chemically induced | Treatment Outcome | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Sulfonamides - pharmacokinetics | BRCA1 Protein - genetics | Maximum Tolerated Dose | Sulfonamides - therapeutic use | Peritoneal Neoplasms - genetics | Aged | Mutation | BRCA2 Protein - genetics | Antimitotic agents | Genetic aspects | Research | Drug therapy | Antineoplastic agents | Slopes | Ovarian carcinoma | Toxicity | Homologous recombination | Poly(ADP-ribose) | Homology | Fallopian tube | Dosage | ADP | Platinum | Ribose | Bioindicators | Toxic diseases | Safety | BRCA2 protein | Appetite | BRCA1 protein | Anemia | Poly(ADP-ribose) polymerase | Fatigue | Radioactive half-life | Nausea | Breast cancer | Pharmacology | Bioavailability | Patients | Polymerase | Sensitivity | Inhibitors | Response rates | Biomarkers | Solid tumors | Pharmacokinetics | Tumors | Peritoneum | Cancer | Index Medicus | Phase I Studies
Journal Article
Investigational New Drugs: the journal of new anti-cancer agents, ISSN 0167-6997, 10/2011, Volume 29, Issue 5, pp. 953 - 962
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2014, Volume 32, Issue 4, pp. 670 - 681
Journal Article
Journal Article
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2013, Volume 31, Issue 3, pp. 751 - 759
This phase I, open-label, dose-escalation study assessed the maximum-tolerated dose, safety, pharmacokinetics, and preliminary antitumor activity of pazopanib... 
Pharmacokinetic interaction | Phase I | Medicine & Public Health | Oncology | Lapatinib | Solid tumors | Pharmacology/Toxicology | Pazopanib |